Novartis
Novartis announced yesterday that it has launched an app specifically designed for eye patients to participate in ophthalmic clinical trials.
Like almost any field in the healthcare industry pharma wants to get in on the latest technology trends.
Predictive analytics platform Clew Medical has recently announced its partnership with WakeMed for its clinical trials in the eICU to detect patient deterioration in realtime.
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia.
Novartis has announced a partnership with Qualcomm Life, a subsidiary of Qualcomm, to develop a connected version of its inhaler, Breezhaler, for people who have COPD.
Los Angeles-based mobile clinical trials company Science 37 has raised $6.
Google and Novartis are working on two smart contact lenses, and news broke this week about both of them: A new patent application sheds light on how Google might power its glucose-sensing contact lens, just a week after partner Novartis told a Swiss newspaper it was on track for human trials in 2016 of an autofocus lens for presbyopia patients.
AstraZeneca has partnered with mobile-enabled health coaching services company Vida to launch an app, called Day-by-Day, that helps patients who are recovering from a heart attack, according to Fortune.
When Apple first announced ResearchKit, it was met with a fair amount of skepticism about whether the data collected via smartphones would be robust enough to be useful.
Novartis has released a new Apple Watch and Android Wear app geared at helping visually-impaired people navigate their environment.